REDWOOD CITY, Calif.,
Nov. 23, 2015 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute pain, today
announced that AcelRx Co-founder and Chief Medical Officer
Pamela Palmer and Chief Financial
Officer Tim Morris will be
presenting at Piper Jaffray 27th Annual Healthcare Conference in
New York. Details of the
conference are as follows:
Piper Jaffray 27th Annual Healthcare
Conference
Date: Tuesday,
December 1
Location: The New York Palace Hotel, New
York
Presentation Time: 1:00 pm ET,
10 am PT
The Piper Jaffray presentation will be webcast live and can be
accessed through the Investors page at www.acelrx.com. For
those not available to listen to the live broadcast, a replay will
be archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute pain. The company's
late-stage pipeline includes ARX-04 (sufentanil sublingual tablet,
30 mcg) for the treatment of moderate-to-severe acute pain in a
medically supervised setting; and Zalviso™ (sufentanil sublingual
tablet system) for the management of moderate-to-severe acute pain
in adult patients in the hospital setting. ARX-04 delivers 30 mcg
sufentanil, a high therapeutic index opioid, sublingually through a
disposable, pre-filled, single-dose applicator. AcelRx has reported
positive results from the pivotal Phase 3 SAP301 ambulatory surgery
study, and has advanced ARX-04 into a study (SAP302) in emergency
room patients. Zalviso delivers 15 mcg sufentanil sublingually
through a non-invasive delivery route via a pre-programmed,
patient-controlled analgesia device. In response to the New Drug
Application (NDA) AcelRx submitted to the U.S. Food and Drug
Administration (FDA) seeking approval for Zalviso, AcelRx received
a Complete Response Letter (CRL) on July 25,
2014. The FDA has requested an additional clinical study and
the Company is working with the FDA regarding the resubmission of
the Zalviso NDA and initiation of a clinical study to support
resubmission.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to the process
and timing of anticipated future development of AcelRx's product
candidates, including the process and timing of anticipated future
development of Zalviso and ARX-04; anticipated results and timing
of the completion of the SAP302 study for ARX-04; AcelRx's plans to
seek a pathway forward towards gaining approval of Zalviso in
the United States; and anticipated
resubmission of the Zalviso NDA to the FDA, including the scope and
timing of resubmission. These forward-looking statements are based
on AcelRx's current expectations and inherently involve significant
risks and uncertainties. AcelRx's actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
any delays or inability to obtain and maintain regulatory approval
of its product candidates, including Zalviso and ARX-04; its
ability to successfully design and complete the additional clinical
study requested by the FDA to support resubmission of the Zalviso
NDA; its ability to timely resubmit the Zalviso NDA to the FDA and
to receive regulatory approval for Zalviso; the fact that the FDA
may dispute or interpret differently positive clinical results
obtained to date from the pivotal Phase 3 SAP301 ambulatory surgery
study of ARX-04; its ability to complete Phase 3 clinical
development of ARX-04; the success, cost and timing of all product
development activities and clinical trials, including the SAP302
ARX-04 trial; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx's U.S. Securities and Exchange Commission
filings and reports, including its Quarterly Report on Form 10-Q
filed with the SEC on November 3,
2015. AcelRx undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events or changes in its
expectations.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-piper-jaffray-27th-annual-healthcare-conference-300182958.html
SOURCE AcelRx Pharmaceuticals, Inc.